Pneumococcal vaccine uptake among Medicare Beneficiaries aged ≥65 years following the shared clinical decision-making recommendation for 13-valent pneumococcal conjugate vaccine in 2019

Matanock, 2019, Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the advisory committee on immunization practices, MMWR Morb Mortal Wkly Rep, 68, 1069, 10.15585/mmwr.mm6846a5 Hong, 2021, Decline in receipt of vaccines by medicare beneficiaries during the COVID-19 pandemic - United States, 2020, MMWR Morb Mortal Wkly Rep, 70, 245, 10.15585/mmwr.mm7007a4 Fergie, 2021, Implementation experience with meningococcal Serogroup B vaccines in the United States: impact of a nonroutine recommendation, Pediatr Infect Dis J, 40, 269, 10.1097/INF.0000000000003033 Okunrintemi, 2019, Association of income disparities with patient-reported healthcare experience, J Gen Int Med, 34, 884, 10.1007/s11606-019-04848-4 Zikmund-Fisher, 2012, Disparities in patient reports of communications to inform decision making in the DECISIONS survey, Patient Educ Couns, 87, 198, 10.1016/j.pec.2011.08.002 Gierke R. Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage among adults, United States. In: Paper presented at: Meeting of the Advisory Committee on Immunization Practices; February 25, 2021; 2021. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71(4): 109–117. Centers for Disease Control and Prevention. Pneumococcal Vaccine Timing for Adults. https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf. Published 2023. Accessed March 15, 2023.